Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in QNCX — Quince Therapeutics, Inc.

CIK 1423053 MIAMI, FL
Back to QNCX Full portfolio

Position in QNCX

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$0
-$104,471,760 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
23 quarters on record

Common Shares in QNCX Over Time

Shares Held

Position Value (USD)

Derivatives in QNCX

reported options exposure · as of Mar 31, 2026
CallValue
$2,704,780
CallShares
133,900
PutValue
$698,920
PutShares
34,600

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,784,241,435 across 374 Biotechnology names.

# Ticker Company Shares Value (USD) Open
1 INSM
INSMED Inc
 2,182,571 $356,894,009
2 ONC
BeOne Medicines Ltd.
 1,032,298 $306,561,536
3 BMRN
Biomarin Pharmaceutical Inc
 4,512,634 $254,918,694
4 JAZZ
Jazz Pharmaceuticals plc
 1,259,444 $238,097,887
5 MDGL
Madrigal Pharmaceuticals, Inc.
 453,843 $237,573,195
6 BBIO
BridgeBio Pharma, Inc.
 3,173,940 $235,696,783
7 TERN
Terns Pharmaceuticals, Inc.
 3,218,810 $169,695,662
8 PTGX
Protagonist Therapeutics, Inc
 1,551,900 $163,570,260

All Filings in QNCX

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $698,920 34,600
2026-03-31 $2,704,780 133,900
2025-12-31 $104,471,760 155,928
2025-12-31 $20,770,000 31,000
2025-09-30 $4,596,600 14,100
2025-09-30 $18,553,964 56,914
2025-06-30 $30,988,650 93,905
2025-03-31 $2,234,400 8,400
2025-03-31 $824,600 3,100
2025-03-31 $10,745,602 40,397
2024-12-31 $1,496,000 4,000
2024-12-31 $17,914,600 47,900
2024-09-30 $1,024,320 6,600
2024-09-30 $16,607,486 107,007
2024-06-30 $14,976,600 99,844
2024-06-30 $60,000 400
2024-06-30 $450,000 3,000
2024-03-31 $339,200 1,600
2024-03-31 $5,608,672 26,456
2023-06-30 $3,822,700 12,700
2023-06-30 $301,000 1,000
2023-03-31 $1,248,000 4,000
2023-03-31 $4,804,800 15,400
2022-12-31 $17,351,880 136,200
2022-12-31 $673,691 5,288
2022-12-31 $3,172,260 24,900
2022-09-30 $37,399,600 140,600
2022-09-30 $7,208,600 27,100
2022-06-30 $13,453,200 30,300
2022-06-30 $55,544,400 125,100
2022-06-30 $57,831,444 130,251
2022-03-31 $114,638,800 92,600
2022-03-31 $200,432,200 161,900
2021-12-31 $332,158,400 131,600
2021-12-31 $702,176,800 278,200
2021-12-31 $158,580,396 62,829
2021-09-30 $1,726,544,424 94,182
2021-09-30 $2,267,668,400 123,700
2021-09-30 $2,296,999,600 125,300
2021-06-30 $656,140,000 61,900
2021-06-30 $2,382,880,000 224,800
2021-03-31 $1,642,968 45,600
2021-03-31 $1,178,793 32,717
2021-03-31 $9,872,220 274,000
2020-12-31 $52,226,400 9,400
2020-12-31 $452,258,400 81,400
2020-12-31 $1,539,567,600 277,100
2020-09-30 $3,034,280,000 303,428
2020-06-30 $3,199,867,080 345,558
2020-03-31 $2,309,818,108 253,214

Report a Problem

Category
Description
Email (optional, for follow-up)